Version: 1.0.0 | Published: 9 May 2025 | Updated: 391 days ago
Documentation
Description:
Covid-19 has had an unprecedented effect on life over the last 3 years. Despite numerous advances in vaccines and treatments for Covid-19 it continues to significantly contribute towards death and poor health in the UK. 5.3% of deaths in the week ending 21st January 2023 were certified as deaths involving Covid-19. Age, frailty, sex, and certain co-morbidities have been identified as predictors of death, critical care admission and changes in residence (new care home placements) on discharge. Additionally, several laboratory markers have been identified as predictors of poor prognosis on admission to hospital.
However, despite these advances in the understanding of the risks to prognosis in patients with Covid-19 there has been no universally accepted prognostication model. PhenoAgeAccel is an epigenetic biomarker of ageing for lifespan and healthspan calculated using readily available laboratory markers. It is a DNA methylation-based biomarker that has been tested in several populations and been found to be highly predictive of death and poor health.
PhenoAgeAccel measured in UK biobank participants predicted the severity of outcomes of those participants when they were diagnosed with Covid-19 more than 10 years later. Several of the components (CRP, white cell count, red cell distribution width) of PhenoAgeAccel have already been identified as predictors of poor prognosis in Covid-19.
PhenoAgeAccel is simple to calculate for inpatients with Covid-19 from routinely collected parameters and could provide a simple method of prognostication that could be automatically calculated at admission.
Coverage
Spatial:
West Midlands
Follow Up:
1 - 10 Years
Pathway:
Acute admissions (medical, surgical and critical care) with Covid-19.
Provenance
Origin
Purposes:
Study
Sources:
Machine generated
Collection Situations:
- Secondary care - Accident and Emergency
- Secondary care - In-patients
- Secondary care - Outpatients
Temporal
Accrual Periodicity:
Static
Distribution Release Date:
20 June 2024
Start Date:
01 February 2020
End Date:
28 February 2021
Time Lag:
More than 6 months
Accessibility
Access
Access Rights:
Information Governance and Ethics - West Midlands Secure Data Environment (https://westmidlandssde.nhs.uk/information-governance-and-ethics)
Access Service:
Data Request Process - West Midlands Secure Data Environment
(https://westmidlandssde.nhs.uk/research/data-request)
Access Request Cost:
Please email wmsde@uhb.nhs.uk
Delivery Lead Time:
2-6 months
Jurisdictions:
GB
Data Controller:
University Hospitals Birmingham NHS Foundation Trust
Data Processor:
University Hospitals Birmingham NHS Foundation Trust
Usage
Data Use Limitations:
General research use
Data Use Requirements:
- Ethics approval required
- Project-specific restrictions
Resource Creators:
This publication uses data from the PATHWAY, an ethically approved Research Data Hub (NRES Reference 22/EE/0161)
Format and Standards
Vocabulary Encoding Schemes:
- ICD10
- SNOMED CT
- OPCS4
Conforms To:
LOCAL
Languages:
en
Formats:
SQL